Zontivity
NDC Package 70347-208-90
Package Information
Zontivity is vorapaxar is used to help prevent heart attacks and strokes in people who have had a heart attack or have poor blood flow (peripheral arterial disease). Marketed by Aralez Pharmaceuticals Us Inc., this product is identified by NDC 70347-208 and is authorized under FDA application NDA204886.
Identification & Billing
- RxCUI: 1537039 - vorapaxar 2.08 MG Oral Tablet
- RxCUI: 1537045 - Zontivity 2.08 MG Oral Tablet
- RxCUI: 1537045 - vorapaxar 2.08 MG Oral Tablet [Zontivity]
- RxCUI: 1537045 - Zontivity 2.08 MG (as vorapaxar sulfate 2.5 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70347 - Aralez Pharmaceuticals Us Inc.
- 70347-208 - Zontivity
- 70347-208-90 - 90 TABLET, FILM COATED in 1 BOTTLE
- 70347-208 - Zontivity
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70347-208). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70347-208-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Zontivity, labeled by Aralez Pharmaceuticals Us Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aralez Pharmaceuticals Us Inc. on May 08, 2014. The current certification is valid through December 31, 2022.
What are the primary indications for this medication?
Vorapaxar is used to help prevent heart attacks and strokes in people who have had a heart attack or have poor blood flow (peripheral arterial disease). It works by blocking certain blood cells called platelets from sticking together and forming harmful blood clots. Harmful blood clots can cause heart attacks, strokes, and other serious problems. This "anti-platelet" effect helps keep blood flowing smoothly in your body.
How is this Aralez Pharmaceuticals Us Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70347020890. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.